NCT00082368View on ClinicalTrials.gov

PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 16, 2004

Primary Completion Date

April 14, 2014

Study Completion Date

April 14, 2014

Conditions
Cancer
Interventions
DRUG

Tariquidar

3 days after initial PET patients will receive tariquidar and repeat imaging.

DRUG

Tc-94m Sestamibi

Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00082368 - PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy | Biotech Hunter | Biotech Hunter